Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON)REDWOOD […]